Hoshi Iryo-Sanki (7634) Q2 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2027 earnings summary
9 Nov, 2026Executive summary
H1 FY2027 revenue rose 6.3% YoY to ¥7,839m; operating income increased 11.0% to ¥958m and attributable net income rose 8.5% to ¥675m.
Broad growth in home healthcare, medical gas and gas-equipment construction offset a decline and larger loss in facility care.
Financial highlights
Revenue was ¥7,839m, gross profit ¥3,920m and operating income ¥958m, versus ¥7,373m, ¥3,750m and ¥864m, respectively, in H1 FY2026.
Ordinary income increased 10.5% YoY to ¥1,013m; net income attributable to owners increased 8.5% to ¥675m.
Comprehensive income fell 29.6% YoY to ¥605m, with other securities valuation differences weighing on other comprehensive income.
Outlook and guidance
FY2027 guidance remains unchanged: revenue ¥15,660m (+0.9%), operating income ¥1,980m (+3.2%), ordinary income ¥2,060m (+3.0%) and attributable net income ¥1,400m (+2.0%).
FY2027 EPS guidance is ¥448.31; forecasts are based on current information and assumptions, and actual results may differ materially.
Latest events from Hoshi Iryo-Sanki
- Q1 FY2027 delivered higher profits on stable revenue, led by home medical and care segments.7634
Q1 2027 - Revenue rose 7.7% but profits fell over 20% year-over-year; guidance unchanged.7634
Q1 2025 - Modest profit growth and stable outlook, with a completed subsidiary merger for efficiency.7634
Q2 2025 - Revenue up 3.1% year-over-year, but profits dipped; outlook and dividend unchanged.7634
Q3 2025 - Modest profit growth driven by home healthcare and medical gas, with stable outlook ahead.7634
Q4 2025 - Revenue up 1.2% year-over-year, operating profit down 1.9%, dividend forecast raised.7634
Q2 2026 - Q1 FY2026 delivered strong profit growth and margin expansion, led by medical gas and home healthcare.7634
Q1 2026 - Revenue up 3.2% year-over-year, but profit margins pressured by rising costs.7634
Q3 2026 - Home-care growth lifted FY Mar 2026 sales, while cost pressure weighed on earnings.7634
Q4 2026